PARP inhibitors are effective in cancer patients with BRCA1 mutations but whether this can extend to BRCA1 wildtype patients by targeting BRCA1 transcriptional regulation is unclear. Here, in preclinical models of pancreatic cancer, the authors identify OFD1 as a transcriptional regulator of BRCA1 via the DREAM complex and as a potential therapeutic target in combination with PARP inhibition.
- Peng Li
- Junjie Ye
- Qing Zhong
